PYC Therapeutics Announces Participation in Upcoming Investor Conferences

SAN DIEGO and PERTH, Australia, Aug. 3, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced that members of the management team will participate in the following healthcare investor conferences:

Wedbush PacGrow Healthcare Conference 2021
Date: Wednesday, August 11
Time: 8:00-8:30 a.m. ET
Panel: Only Have Eyes For You – Ophthalmic Gene Therapy

Canaccord Genuity 41^st Annual Growth Conference
Date: Thursday, August 12
Time: 11:30-11:55 a.m. ET
Format: Podium presentation

H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference
Date: Tuesday, August 17
Time: 7:00-7:30 a.m. ET
Format: Podium presentation

Live webcast links from the Wedbush, Canaccord, and H.C. Wainwright conferences will be available in the "Events" section of the Investor & Media Center page of the Company's website at https://pyctx.com/investor-center/. Replays of the webcasts will be archived on the Company's website following the conferences.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution.  The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS                                                                                                                   
Deborah Elson/Matthew DeYoung                                                                            
Argot Partners                                                                                                          
[email protected]                                                                 
[email protected] 
MEDIA
Leo Vartorella
Argot Partners
[email protected]

SOURCE PYC Therapeutics